Biotage sells facility in Charlottesville, Virginia

Published: 11-Jan-2010
Finance

Swedish analytical and medicinal chemistry supplier Biotage is to move product manufacturing from its factory in Charlottesville, Virginia, US to contract manufacturers and its plant in Cardiff, Wales. The transfer of this business has now been finalised.


Swedish analytical and medicinal chemistry supplier Biotage is to move product manufacturing from its factory in Charlottesville, Virginia, US to contract manufacturers and its plant in Cardiff, Wales. The transfer of this business has now been finalised.

The company has now sold the factory for US$5.5m (Euro 3.8m), which has reduced its losses to approximately US$0.1m. Net after transaction costs, Biotage's cash holdings will increase by approximately US$1.3m.

  • Companies:
  • Biotage
See more

You may also like

Finance

Biotage triples production capacity for vaccine-critical equipment

Read more
The availability of raw materials for vaccine production has been a major bottleneck

Trending Articles

  1. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios
  2. Policy vacuum risks UK becoming a medicines supply backwater The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
  3. Lonza appoints President of Capsules and Health Ingredients Christian Seufert joins from BASF, where he has worked for the last 20 years. Most recently, he held the role of Senior VP for the Global Business Unit Pharma Solutions
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    The pros and cons of distribution agreements For life sciences companies seeking to break into overseas markets, distribution agreements are central to success
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Finance

Biotage triples production capacity for vaccine-critical equipment

The availability of raw materials for vaccine production has been a major bottleneck
Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Regulatory

Policy vacuum risks UK becoming a medicines supply backwater

The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Hi Tech Manufacturing

Johnson Matthey agrees to sell Medical Device Components business

The business has been sold to Montagu Private Equity for USD $700m
Finance

Fusion Pharmaceuticals to be acquired by AstraZeneca for up to $2.4bn

Fusion developed a Targeted Alpha Therapies platform together with linker technology to selectively deliver cancer therapies
Research & Development

AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion

The acquisition will facilitate the development of novel therapeutics for rare endocrine and related diseases
Manufacturing

Almac Sciences awarded Life Sciences Innovative Manufacturing Fund grant

Grant awarded to support the expansion of Almac’s small molecule API manufacturing plant
Subscribe now